Drugs / Atezolizumab
Atezolizumab
also known as
MPDL3280A · Tecentriq · atezo · 0ine2sfd9e · Anti-PD-L1 · Ate · Atez · Atezolizumab component of tecentriq hybreza · +7 more
Monoclonal antibody targets CD274 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 19 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (17) | US (FDA) | TECENTRIQ | — | 2017-04-17 – 2026-05-15 | fda.gov ↗ |
| Approved | EU (EMA) | Tecentriq | — | 2017-09-20 | europa.eu ↗ |
| Approved | US (FDA) | TECENTRIQ | — | 2016-05-18 | fda.gov ↗ |
Trials 668 · started per year
today
US approved 2016
EU approved 2017
1
3
4
9
34
40
69
72
68
75
88
57
64
33
29
20
2
201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials · 1 met primary | ||||||
| Phase 0 | NCT07538128 | Jan 2025 → Nov 2026 expected | glioblastoma | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06098898 | Nov 2023 → Nov 2024 | gastric cancer | Base Therapeutics (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT05423210 | Oct 2022 → Aug 2027 expected | glioblastoma | Stony Brook University | Recruiting | No outcome recorded |
| Phase 0 | NCT04857684 | Jun 2021 → Apr 2026 overdue | hepatocellular carcinoma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04630210 | Feb 2021 → Jan 2025 | breast cancer | Universitaire Ziekenhuizen KU Leuven | Withdrawn | No outcome recorded |
| Phase 0 | NCT04249167 | Jan 2020 → Nov 2021 | triple-negative breast carcinoma | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 0 | NCT04102618 | Mar 2019 → Apr 2022 | breast cancer | Oncolytics Biotech | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03802604 | Dec 2018 → Apr 2022 | breast cancer | SOLTI Breast Cancer Research Group | Completed | Met primary |
| Phase 0 | NCT03208712 | Nov 2017 → Aug 2018 | urothelial carcinoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT02463994 | Oct 2015 → Nov 2018 | non-small cell lung carcinoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1122 trials · 2 met primary | ||||||
| Phase 1 | NCT07170592 | Jan 2027 → Dec 2028 expected | refractory malignant neoplasm | Bionoxx Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06492954 | Oct 2026 → Jun 2027 expected | metachronous osteosarcoma of the bone | Emory University | Recruiting | No outcome recorded |
| Phase 1 | NCT07190833 | Mar 2026 → Dec 2028 expected | refractory malignant neoplasm | Bionoxx Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07113691 | Jan 2026 → Jan 2030 expected | small cell lung carcinoma | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06066138 | Nov 2025 → Jan 2027 expected | alveolar soft part sarcoma, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT07011004 | May 2025 → May 2028 expected | acute myeloid leukemia | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06616623 | Dec 2024 → Dec 2026 | non-small cell lung carcinoma | Dwight Owen | Suspended | No outcome recorded |
| Phase 1 | NCT06488716 | Dec 2024 → Nov 2025 | cancer | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06551142 | Sep 2024 → Oct 2028 expected | neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1 | NCT06444815 | Sep 2024 → Sep 2027 expected | cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma +6 | KaliVir Immunotherapeutics | Recruiting | No outcome recorded |
| Show all 122 trials opens the full record — a long page | ||||||
| Phase 1/296 trials · 1 met primary · 7 missed | ||||||
| Phase 1/2 | NCT07707895 | Oct 2026 → Apr 2030 expected | pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07835737 | Oct 2026 → Oct 2029 expected | hepatocellular carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07407933 | Mar 2026 → Nov 2028 expected | small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07227597 | Jan 2026 → Nov 2030 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07190027 | Nov 2025 overdue | non-small cell lung carcinoma | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06287775 | Apr 2025 → Jul 2029 expected | small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06725121 | Dec 2024 → Jun 2031 expected | hepatocellular carcinoma, invasive carcinoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06439485 | Nov 2024 → Feb 2028 expected | cholangiocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06110572 | Apr 2024 → Jun 2027 expected | small cell lung carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06067061 | Apr 2024 → May 2025 | triple-negative breast carcinoma | Institut Curie | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT05908786 | Dec 2023 → Aug 2025 | hepatocellular carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT06006286 | Aug → Nov 2023 | hepatocellular carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05944237 | Aug 2023 → Dec 2028 expected | castration-resistant prostate carcinoma, colorectal neoplasm, gastric neoplasm, head and neck neoplasm +9 | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04691817 | Jul 2023 → Dec 2026 expected | non-small cell lung carcinoma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06090318 | May 2023 | gastric cancer, head and neck squamous cell carcinoma, melanoma, mesothelioma +4 | Rain Oncology Inc | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05501665 | May 2023 → Feb 2026 overdue | non-small cell lung carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04796012 | Apr 2023 → Jan 2027 expected | rhabdomyosarcoma | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05459129 | Apr 2023 → Aug 2024 | head and neck squamous cell carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT05300282 | Feb 2023 → Dec 2026 expected | Hodgkins lymphoma | Fondazione Italiana Linfomi - ETS | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05765084 | Feb 2023 → Oct 2027 expected | malignant pleural mesothelioma | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05394337 | Feb 2023 → Dec 2028 expected | metastatic malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05286801 | Nov 2022 → Mar 2030 expected | atypical teratoid rhabdoid tumor, epithelioid sarcoma, high grade malignant neoplasm, kidney medullary carcinoma +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05468359 | Nov 2022 → Jun 2032 expected | childhood malignant neoplasm, fibrolamellar hepatocellular carcinoma, refractory malignant neoplasm | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05039281 | Sep 2022 → Dec 2027 expected | gliosarcoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05450562 | Sep 2022 → Dec 2025 | neoplasm | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05276284 | Sep 2022 → Dec 2024 | metastatic malignant neoplasm | Kristoffer Rohrberg | Completed | No outcome recorded |
| Phase 1/2 | NCT05434234 | May 2022 → Apr 2027 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04467723 | May 2022 → Jan 2027 expected | non-small cell lung carcinoma | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05315713 | May 2022 → Jul 2023 | follicular lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05253053 | Apr 2022 → Aug 2024 | cholangiocarcinoma, gallbladder cancer, gastric cancer, prostate cancer +4 | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05191797 | Apr 2022 → Aug 2023 | small cell lung carcinoma | University of Washington | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT05325684 | Apr 2022 → Dec 2023 | — | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05251948 | Mar 2022 → Sep 2025 | gastroesophageal cancer | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 1/2 | NCT05116202 | Feb 2022 → Sep 2023 | melanoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT05000294 | Dec 2021 → Dec 2026 expected | bile duct cancer, breast cancer, gallbladder cancer, neuroendocrine neoplasm +5 | University of Florida | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05109442 | Nov 2021 → Mar 2025 | neoplasm | Affimed GmbH | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT07280377 | Oct 2021 → Jul 2027 expected | anal squamous cell carcinoma, pancreatic ductal adenocarcinoma | Oncolytics Biotech | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05052099 | Oct 2021 → Sep 2024 | biliary tract cancer | University Hospital, Essen | Completed | No outcome recorded |
| Phase 1/2 | NCT04486352 | Oct 2021 → Oct 2026 expected | endometrial cancer | Alliance Foundation Trials, LLC. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04896697 | Sep 2021 → May 2026 | — | Xilio Development, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04639245 | Jul 2021 → Aug 2022 | female breast carcinoma, metastatic malignant neoplasm, non-small cell lung carcinoma, triple-negative breast carcinoma +1 | Fred Hutchinson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04802759 | Jun 2021 → May 2029 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04902040 | Apr 2021 → Feb 2025 | cutaneous melanoma, cutaneous neuroendocrine carcinoma, non-small cell lung carcinoma, renal cell adenocarcinoma +1 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04487756 | Mar 2021 → Sep 2025 | small cell lung carcinoma | Instituto Oncológico Dr Rosell | Completed | No outcome recorded |
| Phase 1/2 | NCT04793399 | Feb → Sep 2021 | chronic myeloid leukemia | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | Terminated | No outcome recorded |
| Phase 1/2 | NCT04440735 | Oct 2020 → Sep 2025 overdue | colorectal cancer, non-small cell lung carcinoma | Kahr Medical | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04471415 | Aug 2020 → Mar 2023 | non-small cell lung carcinoma | Dracen Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04216953 | Feb 2020 → Dec 2024 | soft tissue sarcoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1/2 | NCT04214418 | Feb 2020 → Apr 2022 | digestive system cancer | Columbia University | Terminated | No outcome recorded |
| Phase 1/2 | NCT04166721 | Feb 2020 → Mar 2025 overdue | esophageal cancer, gastric cancer | Royal Marsden NHS Foundation Trust | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03973879 | Feb 2020 → Jan 2024 | malignant glioma | Darell Bigner | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04123470 | Jan 2020 → Jul 2023 | melanoma | Lokon Pharma AB | Completed | No outcome recorded |
| Phase 1/2 | NCT04253145 | Dec 2019 → May 2025 | small cell lung carcinoma | Fundacion Oncosur | Unknown | No outcome recorded |
| Phase 1/2 | NCT04045613 | Aug 2019 → Oct 2022 | urothelial carcinoma | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1/2 | NCT03730012 | Jun 2019 → May 2021 | acute myeloid leukemia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03869190 | Jun 2019 → Oct 2025 | urinary bladder cancer, urothelial carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT03881878 | May 2019 → Oct 2022 | HER2 positive breast carcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT03973333 | May 2019 → Sep 2023 | cancer | Immunocore Ltd | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03830918 | Mar 2019 → Jan 2027 expected | small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03853707 | Mar 2019 → Jan 2023 | female breast carcinoma, triple-negative breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03829501 | Jan 2019 → Oct 2024 | cervical cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma +7 | Kymab Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03555149 | Sep 2018 → Sep 2022 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03721679 | Sep 2018 → Jan 2021 | — | Oncovir, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03673787 | Aug 2018 → Mar 2026 overdue | glioblastoma, metastatic prostate carcinoma | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03637764 | Aug 2018 → May 2022 | neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT03502785 | Jul 2018 → May 2025 | urothelial carcinoma | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT03568656 | Jul 2018 → Jul 2025 | breast cancer, castration-resistant prostate carcinoma, non-small cell lung carcinoma | CellCentric Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03566485 | Jul 2018 → Dec 2020 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03394885 | Jun 2018 → Jul 2020 | ovarian cancer | Duke University | Completed | No outcome recorded |
| Phase 1/2 | NCT03533283 | May 2018 → Oct 2026 expected | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03158389 | May 2018 → Feb 2023 | adult glioblastoma | University Hospital Heidelberg | Completed | Mixed |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03154827 | Jan 2018 → Apr 2020 | acute myeloid leukemia | BioLineRx, Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03337698 | Dec 2017 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03280563 | Dec 2017 → Sep 2024 | breast neoplasm | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT03312530 | Nov 2017 → May 2021 | plasma cell myeloma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT03206047 | Nov 2017 → Nov 2020 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03281369 | Oct 2017 → Oct 2025 | digestive system carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT03174197 | Jun 2017 → Sep 2025 | gliosarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03024437 | Jun 2017 → Jun 2024 | metastatic malignant neoplasm, renal cell carcinoma | Roberto Pili | Terminated | No outcome recorded |
| Phase 1/2 | NCT03138889 | Jun 2017 → Jul 2022 | non-small cell lung carcinoma | Nektar Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03127007 | Apr 2017 → Feb 2024 | rectal neoplasm | Grand Hôpital de Charleroi | Completed | No outcome recorded |
| Phase 1/2 | NCT03023423 | Dec 2016 → May 2018 | non-small cell lung carcinoma | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 1/2 | NCT02989584 | Dec 2016 → Dec 2026 expected | urinary bladder cancer, urothelial carcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | Met primary |
| Phase 1/2 | NCT02729896 | Nov 2016 → Sep 2018 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02935361 | Nov 2016 → Jun 2027 expected | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02705196 | Nov 2016 → Nov 2025 | malignant pancreatic neoplasm | Lokon Pharma AB | Completed | No outcome recorded |
| Phase 1/2 | NCT02926833 | Sep 2016 → Jan 2023 | diffuse large B-cell lymphoma | Kite, A Gilead Company | Completed | No outcome recorded |
| Phase 1/2 | NCT02792192 | Jun 2016 → Sep 2020 | urinary bladder cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT02748889 | Mar 2016 → May 2017 | small cell lung carcinoma | Giuseppe Giaccone | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02630186 | Feb 2016 → Sep 2017 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02631577 | Dec 2015 → Oct 2018 | follicular lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02596971 | Dec 2015 → Apr 2018 | diffuse large B-cell lymphoma, follicular lymphoma, susceptibility to | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02541604 | Nov 2015 → Jun 2019 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02500407 | Sep 2015 → May 2024 | B-cell chronic lymphocytic leukemia | Genentech, Inc. | Completed | Mixed |
| Phase 2322 trials · 19 met primary · 17 missed | ||||||
| Phase 2 | NCT07322341 | Oct 2026 → Nov 2030 expected | non-small cell lung carcinoma | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT07654400 | Jul 2026 → Dec 2027 expected | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07018947 | Jun 2026 → Jun 2031 expected | hepatocellular carcinoma | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 2 | NCT07339059 | Jun 2026 → Feb 2029 expected | small cell lung carcinoma | Bindu R Potugari | Recruiting | No outcome recorded |
| Phase 2 | NCT07363356 | Jan → Oct 2026 expected | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06254248 | Jan 2026 → Jan 2030 expected | hepatocellular carcinoma | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT07235293 | Jan → Sep 2026 overdue | colorectal cancer | Kahr Bio Australia Pty Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07276100 | Jan 2026 → Jan 2027 expected | hepatocellular carcinoma | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Recruiting | No outcome recorded |
| Phase 2 | NCT07224971 | Dec 2025 → May 2027 expected | non-small cell lung carcinoma | Liza Villaruz, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT07239245 | Nov 2025 → Nov 2027 expected | hepatocellular carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Show all 322 trials opens the full record — a long page | ||||||
| Phase 2/312 trials · 1 missed | ||||||
| Phase 2/3 | NCT07285850 | Oct 2025 → Aug 2026 overdue | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07293468 | Apr 2024 → Mar 2034 expected | hepatocellular carcinoma | Tuen Mun Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05770102 | Oct 2023 → Oct 2029 expected | cancer, colorectal neoplasm, endometrium neoplasm, lymphoproliferative syndrome +1 | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05063552 | Mar 2023 → Dec 2027 expected | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, lip and oral cavity squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +5 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05722886 | Mar 2023 → Oct 2029 expected | cancer, hematopoietic and lymphoid cell neoplasm | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05694013 | Feb 2023 → Jun 2024 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2/3 | NCT05058651 | Jun 2022 → Oct 2028 expected | neuroendocrine carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05141721 | Feb 2022 → Mar 2027 expected | colorectal neoplasm | Seattle Project Corporation | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04619797 | Dec 2020 → Apr 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2/3 | NCT03178552 | Sep 2017 → Jun 2027 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | Mixed |
| Phase 2/3 | NCT02839707 | Jun 2017 → May 2023 overdue | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian clear cell adenocarcinoma +5 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01810913 | Mar 2013 → Jan 2027 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded Stop: Enrollment |
| Phase 389 trials · 14 met primary · 18 missed | ||||||
| Phase 3 | NCT07388524 | Mar 2027 → Sep 2032 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT07461675 | Mar 2026 → Jun 2029 expected | hepatocellular carcinoma | University of Geneva, Switzerland | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07166406 | Feb 2026 → Mar 2029 expected | hepatocellular carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06841172 | Jul 2025 → Jul 2027 expected | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT06719336 | Dec 2024 → Dec 2028 expected | small cell lung carcinoma | Anhui Shi, MD | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06632327 | Dec 2024 → Apr 2029 expected | non-small cell lung carcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06733038 | Nov 2024 → Apr 2028 expected | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Recruiting | No outcome recorded |
| Phase 3 | NCT06031597 | Sep 2023 → Dec 2025 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05862285 | Jun 2023 → Mar 2033 expected | cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05482516 | Mar 2023 → Aug 2026 overdue | bile duct adenocarcinoma, colon adenocarcinoma, gallbladder adenocarcinoma, gastric adenocarcinoma +3 | Georgetown University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05425940 | Sep 2022 → Jun 2026 overdue | colorectal cancer | Exelixis | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05047250 | Jun 2022 → Dec 2025 overdue | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04637594 | May 2022 → Jun 2024 overdue | renal pelvis urothelial carcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04996017 | Dec 2021 → Jul 2027 expected | malignant pleural mesothelioma | Italian Oncology Group for Clinical Research | Recruiting | No outcome recorded |
| Phase 3 | NCT05112965 | Dec 2021 → Jun 2027 expected | neoplasm | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05091567 | Nov 2021 → Jul 2024 overdue | small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | Met primary |
| Phase 3 | NCT05055908 | Oct 2021 → Jul 2025 overdue | lung cancer | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04803994 | Jul 2021 → Jul 2027 expected | hepatocellular carcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Phase 3 | NCT04740918 | Jun 2021 → Jun 2024 | breast cancer | Hoffmann-La Roche | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT04873362 | May 2021 → Mar 2027 expected | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04732286 | May 2021 → Apr 2024 | hepatocellular carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT04660344 | May 2021 → Jun 2025 overdue | urinary bladder carcinoma | Hoffmann-La Roche | Active not recruiting | Met primary |
| Phase 3 | NCT04770896 | Apr 2021 → Jun 2026 overdue | hepatocellular carcinoma | Hoffmann-La Roche | Active not recruiting | Missed primary |
| Phase 3 | NCT04712643 | Mar 2021 → Feb 2029 expected | hepatocellular carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04732598 | Jan 2021 → Sep 2025 | breast cancer | Japanese Foundation for Cancer Research | Completed | No outcome recorded |
| Phase 3 | NCT04540211 | Oct 2020 → Feb 2023 | esophageal cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT04446117 | Oct 2020 → Apr 2024 overdue | metastatic prostate carcinoma, prostate adenocarcinoma | Exelixis | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04471428 | Oct 2020 → Sep 2022 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT04543617 | Sep 2020 → Jul 2026 | esophageal squamous cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04487067 | Aug 2020 → Aug 2024 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04513925 | Aug 2020 → May 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT04214262 | Aug 2020 → Aug 2024 overdue | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04338269 | Jul 2020 → Jan 2023 | renal cell carcinoma | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 3 | NCT04194203 | Apr 2020 → Feb 2023 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04102098 | Dec 2019 → Oct 2022 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04148911 | Dec 2019 → Dec 2024 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04177108 | Nov 2019 → Feb 2023 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT03991403 | Aug 2019 → Mar 2023 | non-small cell lung carcinoma | Samsung Medical Center | Unknown | Met primary |
| Phase 3 | NCT04028050 | Aug 2019 → Jul 2023 | small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03811002 | Jul 2019 → Apr 2024 overdue | small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT03977194 | Jul 2019 → Aug 2024 overdue | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03922997 | Jul 2019 → Aug 2022 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03775265 | Jun 2019 → Jun 2027 expected | infiltrating bladder urothelial carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03762018 | Apr 2019 → Sep 2023 | malignant pleural mesothelioma | ETOP IBCSG Partners Foundation | Completed | Missed primary |
| Phase 3 | NCT03199885 | Apr 2019 → Apr 2024 | HER2 positive breast carcinoma, breast adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03768063 | Feb 2019 → Jul 2028 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03799835 | Jan 2019 → Jun 2025 overdue | urinary bladder cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03726879 | Jan 2019 → Feb 2021 | breast cancer | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT03693573 | Jan 2019 → Aug 2021 | renal cell carcinoma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT03735121 | Dec 2018 → Apr 2022 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT03603184 | Oct 2018 → Jan 2025 | endometrial cancer | Mario Negri Institute for Pharmacological Research | Completed | Mixed |
| Phase 3 | NCT03556839 | Sep 2018 → Aug 2025 | cervical carcinoma | Spanish Ovarian Cancer Research Group | Completed | Met primary |
| Phase 3 | NCT03353831 | Sep 2018 → Mar 2025 | ovarian carcinoma | AGO Research GmbH | Completed | Missed primary |
| Phase 3 | NCT03595592 | Sep 2018 → Dec 2026 expected | invasive breast carcinoma | Fondazione Michelangelo | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03498716 | Aug 2018 → Aug 2023 | triple-negative breast carcinoma | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 3 | NCT03755791 | Jun 2018 → Nov 2021 overdue | hepatocellular carcinoma | Exelixis | Active not recruiting | Mixed |
| Phase 3 | NCT03456063 | Apr 2018 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03434379 | Mar 2018 → Aug 2020 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT02997228 | Jan 2018 → Jun 2027 expected | colorectal adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03371017 | Jan 2018 → Oct 2024 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT03281954 | Dec 2017 → Dec 2024 overdue | triple-negative breast carcinoma | NSABP Foundation Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03273153 | Dec 2017 → Apr 2019 | melanoma | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 3 | NCT02912559 | Oct 2017 → Feb 2025 overdue | DNA repair disease, Lynch syndrome, colon adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT03148418 | Sep 2017 → Nov 2026 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03191786 | Sep 2017 → Apr 2022 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT03197935 | Jul 2017 → Apr 2020 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT03038100 | Mar 2017 → Feb 2022 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02908672 | Jan 2017 → Oct 2019 | melanoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT03016312 | Jan 2017 → Jun 2019 | castration-resistant prostate carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT03024996 | Jan 2017 → May 2022 | renal cell carcinoma | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 3 | NCT02928406 | Nov 2016 → Dec 2022 | malignant urinary system neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02891824 | Sep 2016 → Oct 2021 | ovarian cancer | ARCAGY/ GINECO GROUP | Completed | Missed primary |
| Phase 3 | NCT02788279 | Jul 2016 → Mar 2018 | colorectal cancer | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT02813785 | Jul 2016 → Aug 2019 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02807636 | Jun 2016 → Aug 2022 | urothelial carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02763579 | Jun 2016 → Apr 2018 | small cell lung carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT02657434 | Apr 2016 → Jul 2019 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02620280 | Apr 2016 → Jan 2024 | invasive ductal breast carcinoma | Fondazione Michelangelo | Completed | No outcome recorded |
| Phase 3 | NCT02486718 | Oct 2015 → Jan 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02450331 | Oct 2015 → Nov 2019 | transitional cell carcinoma | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 3 | NCT02409342 | Jul 2015 → Feb 2020 | non-small cell squamous lung carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02425891 | Jun 2015 → Apr 2020 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02367794 | Jun 2015 → Oct 2018 | non-small cell squamous lung carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02420821 | May 2015 → Feb 2020 | renal cell carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02409355 | May 2015 → Dec 2017 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02367781 | Apr 2015 → Mar 2018 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT02366143 | Mar 2015 → Sep 2019 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Mixed |
| Phase 3 | NCT02302807 | Jan 2015 → Mar 2017 | urinary bladder cancer | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT02008227 | Mar 2014 → Jul 2016 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 47 trials | ||||||
| Phase 4 | NCT07059494 | Jun 2026 → Aug 2027 expected | hepatocellular carcinoma | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 4 | NCT05689671 | Dec 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Nikolaj Frost MD | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT05717400 | Mar 2023 → Aug 2024 | hepatocellular carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 4 | NCT05185505 | Jan 2023 → Apr 2027 expected | hepatocellular carcinoma | The Methodist Hospital Research Institute | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04059887 | Dec 2019 → Dec 2021 | lung cancer | Chonnam National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03285763 | Oct 2017 → Apr 2022 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07543510 | May 2026 → Aug 2028 expected | hepatocellular carcinoma | Third Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT07281664 | Jan 2026 → Dec 2028 expected | hepatocellular carcinoma | Third Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT05984511 | Aug 2023 → Aug 2028 expected | hepatocellular carcinoma | Third Affiliated Hospital, Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT04801966 | Sep 2021 → Dec 2022 | cancer | Peter MacCallum Cancer Centre, Australia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT07272265 | Oct 2020 → May 2025 | adult hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT04180072 | Mar 2020 → Dec 2025 overdue | hepatocellular carcinoma | National Health Research Institutes, Taiwan | Active not recruiting | No outcome recorded |
| — | NCT03577132 | Aug 2018 → May 2020 | urothelial carcinoma | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT03035890 | Jan 2017 → Jun 2022 | non-small cell lung carcinoma | West Virginia University | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02589717 | Nov 2015 → Aug 2016 | urothelial carcinoma | Genentech, Inc. | Approved for marketing | No outcome recorded |
| Comparator or background therapy122 trials | ||||||
| Phase 0 | NCT06097962 Background | Jul 2023 → Jul 2027 expected | non-small cell lung carcinoma | Base Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT03371992 Background | Mar 2018 → Dec 2020 | non-small cell lung carcinoma | Nilogen Oncosystems | Unknown | No outcome recorded |
| Phase 1 | NCT07545954 Background | Jul 2026 → Aug 2029 expected | small cell lung carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06719973 Background | May 2025 | cancer | EMD Serono Research & Development Institute, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06760481 Background | Apr 2025 → Sep 2028 expected | high grade malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Show all 122 trials opens the full record — a long page | ||||||
Press releases naming this drug 334 releases
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 797 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atezolizumab | “Standard of Care Drugs (at investigator's discretion) may include: pembrolizumab, nivolumab, cemiplimab, durvalumab, dostarlimab, avelumab, and atezolizumab, or other immune...” NCT07224971 ↗779“Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗ “Another recent trial in patients with advanced HCC demonstrated improved survival with the combination of Atezolizumab, an immune checkpoint inhibitor (ICI), and Bevacizumab,...” NCT05137899 ↗ “In this pilot study, the investigators will investigate if Nilogen's functional ex vivo bioassay can predict therapeutic response to anti PD1 (nivolumab, pembrolizumab) or anti...” NCT03371992 ↗ “yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been...” NCT06555133 ↗ “TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab,...” NCT02890368 ↗ “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “MPDL3280A (atezolizumab) is a human monoclonal antibody containing an engineered Fc-domain to optimize efficacy and safety that targets PD-L1 and blocks binding of its...” NCT02620280 ↗ “Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗ “Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day...” NCT05325684 ↗ “ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ |
| Known as | 0ine2sfd9e | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707227 ↗ |
| Known as | Anti-PD-L1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707227 ↗ |
| Known as | Ate | “Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed...” NCT01656642 ↗ |
| Known as | Atez | “Atezolizumab (Atez) combined with bevacizumab (Bev) is the recommended first-line treatment for unresectable hepatocellular carcinoma (HCC).” PMID 40891895 ↗ Sep 2025 |
| Known as | atezo | “This phase 1b study (NCT02431208) evaluated the safety and efficacy of the anti-programmed death-ligand 1 monoclonal antibody atezolizumab (Atezo) alone or in combination with...” PMID 37559718 ↗ Jul 20234“Participants in the atezolizumab plus bevacizumab (Atezo + Bev) arm will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31)...” NCT07018947 ↗ “Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with...” NCT06739252 ↗ “This study evaluated the safety and efficacy of atezolizumab (Atezo) with or without tiragolumab (Tira) after nCRT in patients with LARC.” PMID 41529226 ↗ Jan 2026 “ipatasertib (ipat) in combination with atezolizumab (atezo) and paclitaxel (pac) or nab-paclitaxel” NCT03800836 ↗ |
| Known as | Atezolizumab component of tecentriq hybreza | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707227 ↗ |
| Known as | Atezolizumab-tqjc | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707227 ↗ |
| Known as | ATZ | “4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days” NCT02926833 ↗ |
| Known as | MPDL3280A | “A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and...” NCT02220842 ↗29“A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer,...” NCT02989584 ↗ “A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer” NCT02543645 ↗ “The Anti-PD-L1 Antibody Atezolizumab (MPDL3280A) Administered With Stereotactic Ablative Radiotherapy (SABR) in Patients With Metastatic Tumours” NCT02992912 ↗ “Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody” NCT02367794 ↗ “Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody” NCT02410512 ↗ “Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody” NCT02458638 ↗ “Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody” NCT03280563 ↗ “Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody” NCT02409342 ↗ “Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody” NCT01846416 ↗ “Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody” NCT02302807 ↗ |
| Known as | RG-7446 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707227 ↗ |
| Known as | RO5541267; Tecentriq | “RO5541267; Tecentriq” NCT02596971 ↗ |
| Known as | Tecentriq | “Atezolizumab is an antibody that operates on an important receptor of the immune system (PD1/PD-L1 axis). Atezolizumab (Tecentriq®) has already been approved in a number of...” NCT05052099 ↗23“An Open-Label, Singe Arm, Multicenter Study to Investigate the Safety and Efficacy of Atezolizumab (Tecentriq) in Previously-Treated Patients With Locally Advanced or...” NCT03922997 ↗ “locally approved anticancer regimen containing intravenous atezolizumab (TECENTRIQ, F. Hoffmann-La Roche Ltd/Genentech) and local standard-of-care support” PMID 37076159 ↗ Apr 2023 “Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPOX chemotherapy prior to surgery.” NCT05870800 ↗ “Arm B: TT-00420 tablet in combination with atezolizumab (Tecentriq®) Arm B will enroll patients with advanced biliary tract cancer.” NCT05253053 ↗ “Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer” NCT03835949 ↗ “four cycles of 1200 mg of atezolizumab (Tecentriq®, Roche) and 600 mg of Tiragolumab (Roche) every 3 weeks” NCT06175390 ↗ “two doses of Atezolizumab (Tecentriq), an FDA approved PD- L1 inhibitor drug, 840 mg IV” NCT05423210 ↗ “Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.” NCT04467723 ↗ “Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody” NCT02409342 ↗ “Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody” NCT01846416 ↗ |
| Known as | Tecentriq (atezolizumab) | “Tecentriq (atezolizumab)” NCT04157985 ↗ |
| Known as | TecentriqTM | “Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).” NCT05937295 ↗ |
| Known as | Tencentriq | “Atezolizumab (Tencentriq)” NCT03175432 ↗ |
| Action | Inhibit | “Atezolizumab inhibits PD-L1 signaling” PMID 32586767 ↗ May 2020 |
| Modality | Monoclonal antibody | “The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1” PMID 30347025 ↗ Mar 2019 |
| Route | Intravenous | “Atezolizumab will be administered at a dose of 1200 mg by IV infusion” NCT00781612 ↗ |
| Target | CD274 | “PD-L1 targeting antibody MPDL3280A” NCT02478099 ↗ |